SCM
JUNO

Segantii Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Segantii Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,900
Closed -$87K – 370
2017
Q1 		$87K Buy
+3,900
New +$83.7K 0.01% 216

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Segantii Capital Management's JUNO Position: Q2 2017 in Review

Segantii Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2017, closing a stake of 3,900 shares — an estimated $87K sold.

Segantii Capital Management first reported a position in JUNO in Q1 2017 and held it in 1 quarter. The position peaked at $87K in Q1 2017. 173 funds tracked by Wall St. Rank hold JUNO as of Q2 2017.

  • Segantii Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 3,900 Juno Therapeutics, Inc. shares in Q2 2017, an estimated $87K.
  • Segantii Capital Management first reported a position in Juno Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Juno Therapeutics, Inc. position peaked at $87K in Q1 2017.
  • 173 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.